Clarington Peptides / Archive5 articles
All Articles
01
alcohol use disorder
Tirzepatide and AOD-9604 Synergy for Stubborn Belly Fat
The VA's semaglutide trial for alcohol use disorder hints at brain-reward pathways that could explain GLP-1 non-response in stubborn belly fat. Combining
02
AOD-9604
Semaglutide Compounding Demand Surge After FDA Panel Vote: Using AOD-9604 to Bridge Gaps
An FDA panel vote on GLP-1 shortages triggered a surge in compounded semaglutide orders. Researchers are now exploring AOD-9604 as a potential
03
AOD-9604
Tirzepatide Compounding Risks After FDA Warning: AOD-9604 and CJC-1295 for Plateaus
The FDA’s 2025 warning on compounded tirzepatide reshapes weight loss research. We compare AOD-9604 and CJC-1295 for plateaus, with cycle-aware
04
AOD-9604
Semaglutide Menstrual Changes: Can AOD-9604 Help?
Semaglutide can disrupt menstrual cycles through rapid weight loss and hormonal shifts. Emerging research considers whether AOD-9604 might mitigate
05
GI intolerance
Tirzepatide vs Semaglutide: GI Risk When Restarting After a Break
A 2024 study found restarting tirzepatide or semaglutide at full dose after a 14-day gap raised severe GI events 2.4-fold. Re-titration nearly eliminated the